Loukia Lili
Loukia Lili has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Bodi Zhang
Research and Development Thorne HealthTech, Inc., NYC New York USA
2 shared publicationsNate Rickard
Research and Development Thorne HealthTech, Inc., NYC New York USA
2 shared publications- Akira Torii
Torii Medical Clinic, Setagaya, Tokyo 157-0066, Japan
1 shared publication Benjamin Readhead
ASU‐Banner Neurodegenerative Disease Research Center Arizona State University Tempe Arizona USA
1 shared publicationCem Meydan
Thorne HealthTech, Inc., 152W 57th st, New York, NY 10019, USA
1 shared publication- Hirokazu Yamada
Soiken Inc., Chiyoda, Tokyo 101-0052, Japan
1 shared publication
Latest Publications
- Open Access
- 12 September 2025
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 69 (22) , e70253
An Application of a Large‐Scale, Data‐Driven Approach to Prioritize Compound‐Targeted Conditions in the Nutraceutical Space: Case Study of Quercefit TM (Quercetin Phytosome) Toward Unbalanced Lipid Conditions in Metabolically Challenged Adults
In preventive healthcare, the demand for systematic identification of wellness‐promoting natural compounds is rising. Quercetin, a phenolic compound found in various fruits and vegetables, is known for its antioxidant and anti‐inflammatory properties, improving lipid profiles and metabolic dysfunctions in conditions like Type 2 diabetes and NAFLD. This study applies a novel adaptation of an in‐silico drug repurposing methodology to quercetin, analyzing a gene expression signature library of over 800 diseases and 30 quercetin‐related conditions to prioritize molecular targets. Our findings revealed a strong computational link between quercetin and hypercholesterolemia. To validate this, we conducted a proof‐of‐concept clinical study using a high‐bioaccessibility quercetin formulation (Quercefit TM ) in healthy adults with borderline metabolic profiles, confirming health benefits. This study highlights quercetin's known potential in managing hypercholesterolemia and demonstrates the power of computational methods in advancing natural compound discovery and repositioning. The integration of in‐silico predictions with human studies could pave the way for more precise or alternative use of bioactive compounds in dietary supplements.
- 12 September 2025
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 69 (22) , e70253
Open AccessAn Application of a Large‐Scale, Data‐Driven Approach to Prioritize Compound‐Targeted Conditions in the Nutraceutical Space: Case Study of Quercefit TM (Quercetin Phytosome) Toward Unbalanced Lipid Conditions in Metabolically Challenged Adults
In preventive healthcare, the demand for systematic identification of wellness‐promoting natural compounds is rising. Quercetin, a phenolic compound found in various fruits and vegetables, is known for its antioxidant and anti‐inflammatory properties, improving lipid profiles and metabolic dysfunctions in conditions like Type 2 diabetes and NAFLD. This study applies a novel adaptation of an in‐silico drug repurposing methodology to quercetin, analyzing a gene expression signature library of over 800 diseases and 30 quercetin‐related conditions to prioritize molecular targets. Our findings revealed a strong computational link between quercetin and hypercholesterolemia. To validate this, we conducted a proof‐of‐concept clinical study using a high‐bioaccessibility quercetin formulation (Quercefit TM ) in healthy adults with borderline metabolic profiles, confirming health benefits. This study highlights quercetin's known potential in managing hypercholesterolemia and demonstrates the power of computational methods in advancing natural compound discovery and repositioning. The integration of in‐silico predictions with human studies could pave the way for more precise or alternative use of bioactive compounds in dietary supplements.
- Open Access
Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial
Background/Objectives: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients. Methods: Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4. Results:The IBS-severity scoring system significantly decreased in all patients (−38.0 [95% confidence interval (CI): −53.6, −22.4]; p < 0.001), in patients with IBS-D (−44.5 [95% CI: −70.6, −18.5]; p = 0.004) and IBS-C (−51.2 [95% CI: −79.4, −22.9]; p = 0.002), but not in those with IBS-M (−20.0 [95% CI: −48.0, 8.1]; p = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention. Conclusions: In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.
Open AccessEffect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial
Background/Objectives: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients. Methods: Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4. Results:The IBS-severity scoring system significantly decreased in all patients (−38.0 [95% confidence interval (CI): −53.6, −22.4]; p < 0.001), in patients with IBS-D (−44.5 [95% CI: −70.6, −18.5]; p = 0.004) and IBS-C (−51.2 [95% CI: −79.4, −22.9]; p = 0.002), but not in those with IBS-M (−20.0 [95% CI: −48.0, 8.1]; p = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention. Conclusions: In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.